Pubescenoside D Ameliorates Myocardial Ischemia–Reperfusion Injury via Preventing the Dissociation of HK2 and Promoting Mitophagy by Targeting GSK ‐3β
Phytotherapy Research · 2025-03 · 39 (3) · 1578-1591
DOI: 10.1002/ptr.8434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 06.02.2025. Verfasst von Juanlan Xiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Translational Cancer Research of Chinese Medicines, Joint International Research Laboratory of Translational C…. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3 beta, Myocardial Reperfusion Injury, Hexokinase, Mitophagy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, the Key-Area Research and Development Program of Guangdong Province.
Abstract (Originalsprache)
Myocardial ischemia–reperfusion injury (MI/RI) is a critical challenge for acute myocardial infarction therapy, as there is currently no ideal drug available. Glycogen synthase kinase 3 beta (GSK‐3β) serves as an promising therapeutic target for treating MI/RI. Our previous studies have demonstrated that Ilex pubescens ameliorates MI/RI. The purpose of this study is to evaluate the therapeutic efficacy and potential mechanism of the screened GSK‐3β inhibitor from Ilex pubescens against MI/RI. Three‐dimensional‐quantitative structure–activity relationship (3D‐QSAR) modeling, molecular docking, the oxygen and glucose deprivation/reperfusion (OGD/R) and left anterior descending (LAD) artery ligation‐induced MI/RI mice model, and western blotting analysis were used to screen and investigate the myocardial protective efficacy and mechanism. Here, we screened Pubescenoside D (PBD) as a GSK‐3β inhibitor with an IC50 value of 0.3769 μM from Ilex pubescens, using 3D‐QSAR modeling, molecular docking, and kinase assay verification. Ile217, Leu88, Phe93, and Phe67 are the key binding sites for PBD and GSK‐3β. PBD protects cardiomyocytes against MI/RI in vitro and in vivo. Further mechanism studies show that PBD inhibits mitochondrial permeability transition pore (mPTP) opening by preventing GSK‐3β‐mediated the dissociation of hexokinase2 (HK2) from the outer membrane of the mitochondria and enhances mitophagy by suppressing GSK‐3β activity, subsequently reducing cardiomyocyte apoptosis. Our findings shed light on the efficacy of PBD as a promising therapeutic agent in the treatment of MI/RI targeting GSK‐3β.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Translational Cancer Research of Chinese Medicines, Joint International Research Laboratory of Translational Cancer Research of Chinese Medicines, International Institute for Trans…
ORCID-Profile: Yuanyuan Cheng
Förderung
- the National Natural Science Foundation of China
- the Key-Area Research and Development Program of Guangdong Province
Zitieren
APA
Xiao, J., Wu, P., Wang, L., Luo, J., Wang, Y., Cheng, Y., Zhang, R., & Liu, Z. (2025). Pubescenoside D Ameliorates Myocardial Ischemia–Reperfusion Injury via Preventing the Dissociation of HK2 and Promoting Mitophagy by Targeting GSK ‐3β. Phytotherapy Research, 39(3), 1578-1591. https://doi.org/10.1002/ptr.8434
Vancouver
Xiao J, Wu P, Wang L, Luo J, Wang Y, Cheng Y, et al. Pubescenoside D Ameliorates Myocardial Ischemia–Reperfusion Injury via Preventing the Dissociation of HK2 and Promoting Mitophagy by Targeting GSK ‐3β. Phytotherapy Research. 2025;39(3):1578-1591. doi:10.1002/ptr.8434
BibTeX
@article{Xiao2025,
author = {Xiao, Juanlan and Wu, Peng and Wang, Lili and Luo, Jianmin and Wang, Ying and Cheng, Yuanyuan and Zhang, Rong and Liu, Zhongqiu},
title = {Pubescenoside D Ameliorates Myocardial Ischemia–Reperfusion Injury via Preventing the Dissociation of HK2 and Promoting Mitophagy by Targeting GSK ‐3β},
journal = {Phytotherapy Research},
year = {2025},
volume = {39},
number = {3},
pages = {1578--1591},
doi = {10.1002/ptr.8434}
}
EUVIMED